Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
1.160
-0.010 (-0.85%)
Dec 5, 2025, 4:00 PM EST - Market closed
Mainz Biomed Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 0.66 | 0.89 | 0.9 | 0.53 | 0.58 | 0.49 | Upgrade
|
| Revenue Growth (YoY) | -28.05% | -0.17% | 69.00% | -8.22% | 16.98% | 75.40% | Upgrade
|
| Cost of Revenue | 0.21 | 0.32 | 0.39 | 0.35 | 0.4 | 0.37 | Upgrade
|
| Gross Profit | 0.45 | 0.57 | 0.51 | 0.18 | 0.18 | 0.12 | Upgrade
|
| Selling, General & Admin | 11.5 | 13.15 | 17.56 | 21.61 | 9.42 | 0.48 | Upgrade
|
| Research & Development | 5.65 | 5.84 | 9.59 | 5.02 | 0.48 | 0.31 | Upgrade
|
| Operating Expenses | 17.15 | 18.99 | 27.15 | 26.63 | 9.9 | 0.8 | Upgrade
|
| Operating Income | -16.7 | -18.42 | -26.64 | -26.44 | -9.72 | -0.67 | Upgrade
|
| Interest Expense | -0.63 | -1.08 | -0.56 | -0.29 | -0.34 | -0.27 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.11 | 0.14 | 0.2 | 0.35 | 0.39 | 0.33 | Upgrade
|
| EBT Excluding Unusual Items | -17.22 | -19.35 | -27.01 | -26.39 | -9.67 | -0.62 | Upgrade
|
| Merger & Restructuring Charges | -0.28 | -0.28 | - | - | -2.02 | 0.03 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.03 | 0.03 | - | - | - | - | Upgrade
|
| Other Unusual Items | -1.5 | -2.05 | 0.71 | - | - | - | Upgrade
|
| Pretax Income | -18.97 | -21.65 | -26.3 | -26.39 | -11.69 | -0.59 | Upgrade
|
| Net Income | -18.97 | -21.65 | -26.3 | -26.39 | -11.69 | -0.59 | Upgrade
|
| Net Income to Common | -18.97 | -21.65 | -26.3 | -26.39 | -11.69 | -0.59 | Upgrade
|
| Shares Outstanding (Basic) | 2 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 2 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 351.86% | 138.45% | 14.73% | 96.34% | 28.60% | - | Upgrade
|
| EPS (Basic) | -8.39 | -22.36 | -64.76 | -74.55 | -64.85 | -4.19 | Upgrade
|
| EPS (Diluted) | -8.39 | -22.36 | -64.76 | -74.55 | -64.85 | -4.19 | Upgrade
|
| Free Cash Flow | -15.45 | -17.19 | -23.14 | -15.43 | -3.24 | -0.48 | Upgrade
|
| Free Cash Flow Per Share | -6.83 | -17.76 | -56.98 | -43.59 | -17.96 | -3.41 | Upgrade
|
| Gross Margin | 67.50% | 64.31% | 56.92% | 34.38% | 30.76% | 24.94% | Upgrade
|
| Operating Margin | -2530.90% | -2060.23% | -2975.47% | -4990.60% | -1684.36% | -136.50% | Upgrade
|
| Profit Margin | -2874.69% | -2421.80% | -2936.50% | -4979.90% | -2024.79% | -118.91% | Upgrade
|
| Free Cash Flow Margin | -2340.66% | -1923.39% | -2583.83% | -2911.63% | -560.67% | -96.93% | Upgrade
|
| EBITDA | -16.15 | -17.71 | -26.07 | -26.06 | -9.65 | -0.61 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -124.25% | Upgrade
|
| D&A For EBITDA | 0.56 | 0.71 | 0.57 | 0.38 | 0.07 | 0.06 | Upgrade
|
| EBIT | -16.7 | -18.42 | -26.64 | -26.44 | -9.72 | -0.67 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -136.50% | Upgrade
|
| Revenue as Reported | 0.66 | 0.89 | 0.9 | 0.53 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.